Biosimilars – Current Treatment – Oncology
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by Celltrion / Teva’s Truxima (rituximab biosimilar), Biocon / Mylan’s Ogivri (trastuzumab biosimilar), and Pfizer’s Zirabev (bevacizumab biosimilar). Several additional MAb biosimilars have appeared since in the U.S. market, including the rituximab biosimilars Ruxience and Riabni and the trastuzumab biosimilars Trazimera, Herzuma, and Ontruzant. Following the launch of rituximab biosimilars in Europe in 2017, several trastuzumab and bevacizumab biosimilars have expanded the European oncology biosimilars market. Uptake of these MAbs, granulocyte colony-stimulating factor (G-CSF), and erythropoiesis-stimulating agent (ESA) biosimilars will depend on oncologists’ prescribing behavior. To help manufacturers / marketers of oncology biosimilars and brands understand the opinions, actions, and expectations of these physicians, Clarivate has conducted new primary market research with oncologists in France, Germany, and the United States on the use of branded drugs versus their biosimilar competitors.
Questions answered
- What is the current patient share of oncology biosimilars, and what expectations do oncologists have about future patient shares, assuming additional biosimilars launch?
- How similar do oncologists believe biosimilars are to their reference brands?
- What factors do oncologists identify as being the key drivers and barriers to biosimilar uptake?
- What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
- What cost reduction is required for a biosimilar to achieve more than a 50% patient share?
Content highlights
Key markets covered: United States, France, Germany
Key companies mentioned: Accord Healthcare, Amgen, Apotex, Biogen, Bristol Myers Squibb, Celltrion, Coherus Biosciences, Genentech, Johnson & Johnson, Merck & Co., Mundipharma, Novartis, Pfizer, Roche, Sandoz, STADA, Teva, Viatris
Key drugs mentioned: Abevmy, Alymsys, Aranesp, Avastin, Aybintio, Binocrit, Cegfila, Epogen, Eprex, Erbitux, Erypo, Fulphila, Granix, Granocyte, Grastofil / Accofil, Grasustek, Herceptin, Herzuma, Kanjinti, Lonquex, Mvasi, NeoRecormon, Neulasta, Neupogen, Nivestim / Nivestym, Nyvepria, Ontruzant, Oyavas, Pelmeg, Pelgraz, Perjeta, Retacrit, Riabni, Rituxan / MabThera, Rixathon, Ruxience, Silapo, Stimufend, Trazimera, Truxima, Udenyca, Vectibix, Vegzelma, Yervoy, Zarzio / Zarxio, Ziextenzo, Zirabev
Product description
Current Treatment: Biosimilars in Oncology provides oncologists’ insights on treatment dynamics, prescribing behavior, and drivers of biosimilar use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
